Inphi’s IPO the highlight of Wall St. week
Inphi Corp.’s initial public offering was an unmitigated success during a volatile month in a volatile year for the markets, experts said.
Amgen gets sought-after FDA approval
The Food and Drug Administration has approved the use of Amgen’s bone drug denosumab in patients with certain types of cancer, Amgen announced Nov. 18.
Inphi shares climb on first day
Shares of Inphi Corp., the Santa Clara-based chipmaker with big operations in Westlake Village, shot up nearly 28 percent to close at $15.30 after they hit the market Nov. 11. Shares of the initial public offering made their debut on the New York Stock Exchange under the symbol IPHI. The 6.8 million shares hit the Read More →
Heritage Oaks reports $11.3M loss
Paso Robles-based Heritage Oaks Bancorp reported a third-quarter loss applicable to common shareholders of $11.3 million on Nov. 9, compared to a $5.6 million loss in the same quarter last year. The banking firm, the third largest based in the Tri-Counties, blamed the wider loss on a $10.5 million non-cash charge related to the valuation Read More →
Inphi predicts $10-$12 IPO price
Inphi Corp., the chip design firm with a big presence in Ventura County, expects the shares of its initial public offering to sell for between $10 and $12. With shares scheduled to hit the market as early as Nov. 10, Inphi would raise $74.8 million if investors buy in the middle of its range. It Read More →
